LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Elenco Azioni・Cytokinetics Inc

Cytokinetics Inc

Chiusa

SettoreSettore sanitario

75.84 -3.46

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

75.36

Massimo

76.26

Metriche Chiave
By Trading Economics
Entrata	-23M -206M
Vendite	1.6M 19M
EPS	-1.67
Margine di Profitto	-1,064.485
Dipendenti	673
EBITDA	112K -180M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+32.08% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	1.9B 10B
Apertura precedente	79.3
Chiusura precedente	75.84

Notizie sul Sentiment di mercato

By Acuity

45%

55%

117 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

32.3 / 40.43 Supporto e resistenza

Cytokinetics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 mag 2026, 23:53 UTC

Acquisizioni, Fusioni, Takeovers

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 mag 2026, 22:47 UTC

Azioni calde

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mag 2026, 22:16 UTC

Acquisizioni, Fusioni, Takeovers

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mag 2026, 22:00 UTC

I principali Market Mover

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mag 2026, 18:09 UTC

I principali Market Mover

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 mag 2026, 23:50 UTC

Discorsi di Mercato

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 mag 2026, 23:43 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

17 mag 2026, 23:43 UTC

Discorsi di Mercato

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 mag 2026, 23:36 UTC

Discorsi di Mercato

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 mag 2026, 23:07 UTC

Acquisizioni, Fusioni, Takeovers

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 mag 2026, 23:06 UTC

Acquisizioni, Fusioni, Takeovers

UOB: Share Sale Agreements Entered With Singland Properties

17 mag 2026, 23:05 UTC

Acquisizioni, Fusioni, Takeovers

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 mag 2026, 22:31 UTC

Acquisizioni, Fusioni, Takeovers

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 mag 2026, 22:31 UTC

Acquisizioni, Fusioni, Takeovers

Prudential PLC to Acquire Stake for $389 Million

17 mag 2026, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 mag 2026, 16:27 UTC

Acquisizioni, Fusioni, Takeovers

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 mag 2026, 15:26 UTC

Acquisizioni, Fusioni, Takeovers

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 mag 2026, 08:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

15 mag 2026, 22:17 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mag 2026, 21:59 UTC

Acquisizioni, Fusioni, Takeovers

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mag 2026, 21:50 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mag 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mag 2026, 21:16 UTC

Discorsi di Mercato

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mag 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

15 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

15 mag 2026, 20:19 UTC

Azioni calde

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mag 2026, 19:41 UTC

Acquisizioni, Fusioni, Takeovers

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mag 2026, 19:35 UTC

Discorsi di Mercato

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mag 2026, 19:33 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mag 2026, 18:35 UTC

Utili

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Cytokinetics Inc Previsione

Obiettivo di Prezzo

By TipRanks

32.08% in crescita

Previsioni per 12 mesi

Media 100.18 USD 32.08%

Alto 140 USD

Basso 67 USD

Basato su 19 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cytokinetics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

19 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 19 che hanno fornito valutazioni azionarie a Cytokinetics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

32.3 / 40.43Supporto e resistenza

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

117 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.